Please assess the completion status of the following clinical trial:

Trial Title: Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genetically confirmed CDKL5 gene mutation, seizure onset by 1 year of age and lack of independent ambulation by 2 years of age~* Failure to control seizures despite 2 or more anti-seizure medications~* At least 16 seizures per 28 days of primary seizure types~* On a stable regimen of 0-4 anti-seizure medications (Vagus nerve stimulator, ketogenic diet, and modified Atkins diet do not count towards this limit)~* Additional Inclusion Criteria apply and can be discussed with study team~Exclusion Criteria:~* Previous exposure to ganaxolone~* West Syndrome with hypsarrhythmia pattern on EEG or seizures predominantly of Infantile Spasms type~* Use of adrenocorticotropic hormone (ACTH), prednisone or other glucocorticoid or use of moderate or strong inducers or inhibitors of CYP3A4/5/7 are prohibited~* Use of tetrahydrocannabinol (THC) or cannabidiol (CBD) is prohibited during the double-blind phase, unless patient has a prescription of Epidiolex®~* Exposure to any other investigational drug within 30 days or fewer than 5 half-lives prior to screening~* Plasma allopregnanolone-sulfate (Allo-S) levels greater than or equal to 6.0 ng/ml at screening visit~* Additional Exclusion Criteria apply and can be discussed with study team

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Ganaxolone (Type: EXPERIMENTAL): ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo suspension 3x's /day for 17 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).